Metabolic dysfunction-associated fatty liver disease in the elderly with diabetic foot ulcers: A longitudinal cohort study

被引:0
|
作者
Zhang, Liya [1 ]
Lin, Yuanmei [2 ]
Huang, Xiuxian [2 ]
Zhai, Zhenwei [2 ]
Wei, Rongyan [2 ]
Mo, Jiacheng [3 ,4 ]
Li, Junjun [5 ,6 ]
Lu, Wensheng [2 ,7 ]
机构
[1] Shanxi Yingkang Healthcare Gen Hosp, Dept Endocrinol, Yuncheng, Peoples R China
[2] Guangxi Acad Med Sci, Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Endocrinol & Metab, Nanning, Peoples R China
[3] Guangxi Acad Med Sci, Informat Network Ctr, Nanning, Peoples R China
[4] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[5] Guangxi Acad Med Sci, Peoples Hosp Guangxi Zhuang Autonomous Reg, Deans Off, Nanning, Peoples R China
[6] Guangxi Acad Med Sci, Peoples Hosp Guangxi Zhuang Autonomous Reg, Deans Off, Nanning 530021, Guangxi, Peoples R China
[7] Guangxi Acad Med Sci, Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Endocrinol & Metab, Nanning 530021, Guangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
diabetic foot ulcers; metabolic dysfunction-associated fatty liver disease; ulcer recurrence; CLASSIFICATION; COMPLICATIONS;
D O I
10.1111/iwj.14586
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
This study aimed to explore the association between metabolic-associated fatty liver disease (MAFLD) and ulcer recurrence risk in patients with diabetic foot ulcers (DFUs) through an ambispective longitudinal cohort. From December 2013 to December 2022, a total of 482 inpatients with DFUs (PEDIS grade 3 and above with a severe infection) were eligible for inclusion in this study. This was an ambispective longitudinal cohort study. All participants were followed up every 6 months for 9 years with a median of 36 months. According to whether having MAFLD or not, all subjects were placed into two groups: non-MAFLD (n = 351) and MAFLD (n = 131). The association between MAFLD and ulcer recurrence in patients with DFUs was then evaluated through multivariate Cox regression analysis, stratified analyses and Kaplan-Meier survival analysis. Throughout the follow-up period, out of 482 subjects with DFUs, 68 had ulcer recurrence (14.1%). Three Cox regression models were established for data analyses. In the model I (unadjusted), MAFLD was significantly associated with the ulcer recurrence rate in patients with DFUs (HR = 1.79; 95% CI = 1.097-2.92; p = 0.02). Model II (adjusted model I with gender and age) (HR = 1.781; 95% CI = 1.09-2.912; p = 0.021) and model III (adjusted model II with CVD, duration of diabetes and Cr.) (HR = 1.743; 95% CI = 1.065-2.855; p = 0.027) also showed that MAFLD was significantly related to the ulcer recurrence risk in patients with DFUs, respectively. Stratified analysis indicated that subjects aged >= 60 had a greater risk of ulcer recurrence in MAFLD than in non-MAFLD (HR = 2.31; 95% CI = 1.268-4.206; p = 0.006). Kaplan-Meier survival curve analysis showed that ulcer recurrence rate had a significant association with MAFLD (log-rank, p = 0.018). This study indicated a close association between ulcer recurrence risk and MAFLD in patients with DFUs, especially in the elderly (aged >= 60). Therefore, special attention should be paid to the elderly with both DFUs and MAFLD because they have a higher ulcer recurrence rate than other general populations in routine clinical practice.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease
    Perdomo, Carolina M.
    Nunez-Cordoba, Jorge M.
    Ezponda, Ana
    Mendoza, Francisco J.
    Ampuero, Javier
    Bastarrika, Gorka
    Fruhbeck, Gema
    Escalada, Javier
    FRONTIERS IN MEDICINE, 2022, 9
  • [32] Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
    Fouad, Yasser
    Alboraie, Mohamed
    Shiha, Gamal
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 827 - 833
  • [33] The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Goya, Takeshi
    Imoto, Koji
    Tashiro, Shigeki
    Aoyagi, Tomomi
    Takahashi, Motoi
    Kurokawa, Miho
    Suzuki, Hideo
    Tanaka, Masatake
    Kato, Masaki
    Kohjima, Motoyuki
    Ogawa, Yoshihiro
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (01) : 20 - 26
  • [34] METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IS ASSOCIATED WITH INCREASED RISK OF LIVER-RELATED COMPLICATIONS: A NATIONWIDE COHORT STUDY
    Shin, Hyunjae
    Park, Min Kyung
    Moon, Hye-Sung
    Chung, Sung Won
    Ko, Yunmi
    Park, Youngsu
    Park, Jeayeon
    Hur, Moon Haeng
    Bin Lee, Yun
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    HEPATOLOGY, 2023, 78 : S1012 - S1013
  • [35] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Ting-Yao Wang
    Rui-Fang Wang
    Zhi-Ying Bu
    Giovanni Targher
    Christopher D. Byrne
    Dan-Qin Sun
    Ming-Hua Zheng
    Nature Reviews Nephrology, 2022, 18 : 259 - 268
  • [36] The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
    Barrera, Francisco
    Uribe, Javier
    Olvares, Nixa
    Huerta, Paula
    Cabrera, Daniel
    Romero-Gomez, Manuel
    ANNALS OF HEPATOLOGY, 2024, 29 (04)
  • [37] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Wang, Ting-Yao
    Wang, Rui-Fang
    Bu, Zhi-Ying
    Targher, Giovanni
    Byrne, Christopher D.
    Sun, Dan-Qin
    Zheng, Ming-Hua
    NATURE REVIEWS NEPHROLOGY, 2022, 18 (04) : 259 - 268
  • [38] Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study
    Peng, Yu
    Wang, Peng
    Liu, Fubin
    Wang, Xixuan
    Si, Changyu
    Gong, Jianxiao
    Zhou, Huijun
    Gu, Jiale
    Qin, Ailing
    Song, Weijie
    Song, Fangfang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1940 - 1949
  • [39] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [40] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    A Lum Han
    Diabetology & Metabolic Syndrome, 14